Home > Uncategorized > FTC Files Amicus Brief That “No-AG” Agreements Are Used by Drug Companies to Delay Generic Competition

FTC Files Amicus Brief That “No-AG” Agreements Are Used by Drug Companies to Delay Generic Competition

August 14, 2012

The Federal Trade Commission filed an amicus brief before the U.S. District Court for the District of New Jersey explaining that an agreement to pay a generic patent challenger for agreeing that it will delay or not launch its own generic drug alternative as a patent litigation settlement is a method to pay generic patent challengers to delay their entry into the market.  The issue before the court is whether such an agreement is or can be an unreasonable restraint of trade.  For the link to the FTC website and release, Click Here.

Dave Tate, Esq. (San Francisco)

Advertisements
Categories: Uncategorized